Report cover image

Generics North America (NAFTA) Industry Guide 2019-2028

Publisher MarketLine
Published Dec 20, 2024
Length 198 Pages
SKU # MTLN19599834

Description

Generics North America (NAFTA) Industry Guide 2019-2028Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights
  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $88,125.3 million in 2023.The Canada was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
  • Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $74,229.0 million in 2023. This was followed by Canada and Mexico, with a value of $7,717.8 and $6,178.6 million, respectively.
  • The US is expected to lead the generics industry in the NAFTA bloc, with a value of $98,531.3 million in 2028, followed by Canada and Mexico with expected values of $10,446.0 and $7,720.0 million, respectively.
Scope
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
  • Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country
Reasons to Buy
  • What was the size of the NAFTA generics market by value in 2023?
  • What will be the size of the NAFTA generics market in 2028?
  • What factors are affecting the strength of competition in the NAFTA generics market?
  • How has the market performed over the last five years?
  • How large is the NAFTA generics market in relation to its regional counterparts?

Table of Contents

198 Pages
1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions
2 NAFTA Generics
2.1. Industry Outlook
3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis
4 Macroeconomic Indicators
4.1. Country data
5 Generics in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis
6 Macroeconomic Indicators
6.1. Country data
7 Generics in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis
8 Macroeconomic Indicators
8.1. Country data
9 Company Profiles
9.1. Teva Pharmaceutical Industries Ltd
9.2. Viatris Inc
9.3. Sun Pharmaceutical Industries Ltd
9.4. Novartis AG
9.5. Sandoz Group AG
9.6. Hikma Pharmaceuticals Plc
9.7. Sanofi
9.8. Les Laboratoires Servier SAS
9.9. Stada Arzneimittel AG
9.10. Bayer AG
9.11. Lupin Ltd
9.12. Aspen Pharmacare Holdings Ltd
9.13. EMS SA
9.14. Eurofarma Laboratorios SA
9.15. Ache Laboratorios Farmaceuticos SA
9.16. Apotex Inc
9.17. Teva Canada Ltd
9.18. Sandoz Canada Inc
9.19. CSPC Pharmaceutical Group Ltd
9.20. Sino Biopharmaceutical Ltd
9.21. Hansoh Pharmaceutical Group Co Ltd
9.22. Dr. Reddy's Laboratories Ltd
9.23. Cipla Ltd
9.24. Aurobindo Pharma Ltd
9.25. PT Kalbe Farma Tbk
9.26. PT Indofarma Tbk
9.27. PT Sanbe Farma
9.28. PT Soho Global Health Tbk
9.29. Friulchem SpA
9.30. DOC Generici SRL
9.31. Recordati SpA
9.32. Daiichi Sankyo Co Ltd
9.33. Towa Pharmaceutical Co Ltd
9.34. Sawai Group Holdings Co Ltd
9.35. Toho Holdings Co Ltd
9.36. Laboratorios Silanes SA de CV
9.37. Pfizer Inc
9.38. Biocad
9.39. R-Pharm
9.40. Pharmstandard
9.41. AstraZeneca Plc
9.42. Bluefish Pharmaceuticals AB
9.43. Navamedic ASA
9.44. Novartis International AG
9.45. Beacons Pharmaceuticals Pte Ltd
9.46. Abbott Laboratories SA
9.47. Adcock Ingram Holdings Ltd
9.48. Dongkook Pharmaceutical Co Ltd
9.49. JW Holdings Corp
9.50. Hanmi Pharmaceuticals Co Ltd
9.51. Dong Wha Pharma Co Ltd
9.52. Esteve Pharmaceuticals SA
9.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
9.54. Deva Holding AS
9.55. Sandoz Inc
10 Appendix
10.1. Methodology
10.2. About MarketLine
List of Tables
Table 1: NAFTA countries generics industry, revenue ($m), 2019-28
Table 2: NAFTA countries generics industry, revenue ($m), 2019-23
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2023-28
Table 4: Canada generics market value: $ million, 2018-23
Table 5: Canada generics market volume: % of total pharma volume, 2018-23
Table 6: Canada generics market geography segmentation: $ million, 2023
Table 7: Canada generics market value forecast: $ million, 2023-28
Table 8: Canada generics market volume forecast: % of total pharma volume, 2023-28
Table 9: Canada Size of Population (million), 2019-23
Table 10: Canada real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 11: Canada GDP (Current Prices, $ Billion), 2019-23
Table 12: Canada Inflation, 2019-23
Table 13: Canada Consumer Price Index (Absolute), 2019-23
Table 14: Canada exchange rate, 2018-23
Table 15: Mexico generics market value: $ million, 2018-23
Table 16: Mexico generics market volume: % of total pharma volume, 2018-23
Table 17: Mexico generics market geography segmentation: $ million, 2023
Table 18: Mexico generics market value forecast: $ million, 2023-28
Table 19: Mexico generics market volume forecast: % of total pharma volume, 2023-28
Table 20: Mexico Size of Population (million), 2019-23
Table 21: Mexico real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 22: Mexico GDP (Current Prices, $ Billion), 2019-23
Table 23: Mexico Inflation, 2019-23
Table 24: Mexico Consumer Price Index (Absolute), 2019-23
Table 25: Mexico exchange rate, 2018-23
Table 26: United States generics market value: $ million, 2018-23
Table 27: United States generics market volume: % of total pharma volume, 2018-23
Table 28: United States generics market geography segmentation: $ million, 2023
Table 29: United States generics market value forecast: $ million, 2023-28
Table 30: United States generics market volume forecast: % of total pharma volume, 2023-28
Table 31: United States Size of Population (million), 2019-23
Table 32: United States real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 33: United States GDP (Current Prices, $ Billion), 2019-23
Table 34: United States Inflation, 2019-23
Table 35: United States Consumer Price Index (Absolute), 2019-23
Table 36: United States exchange rate, 2018-23
Table 37: Teva Pharmaceutical Industries Ltd: key facts
Table 38: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 39: Teva Pharmaceutical Industries Ltd: Key Employees
Table 40: Viatris Inc: key facts
Table 41: Viatris Inc: Annual Financial Ratios
Table 42: Viatris Inc: Key Employees
Table 43: Sun Pharmaceutical Industries Ltd: key facts
Table 44: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 45: Sun Pharmaceutical Industries Ltd: Key Employees
Table 46: Novartis AG: key facts
Table 47: Novartis AG: Annual Financial Ratios
Table 48: Novartis AG: Key Employees
Table 49: Sandoz Group AG: key facts
Table 50: Sandoz Group AG: Key Employees
Table 51: Hikma Pharmaceuticals Plc: key facts
Table 52: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 53: Hikma Pharmaceuticals Plc: Key Employees
Table 54: Sanofi: key facts
Table 55: Sanofi: Annual Financial Ratios
Table 56: Sanofi: Key Employees
Table 57: Les Laboratoires Servier SAS: key facts
Table 58: Les Laboratoires Servier SAS: Key Employees
Table 59: Stada Arzneimittel AG: key facts
Table 60: Stada Arzneimittel AG: Key Employees
Table 61: Bayer AG: key facts
Table 62: Bayer AG: Annual Financial Ratios
Table 63: Bayer AG: Key Employees
Table 64: Bayer AG: Key Employees Continued
Table 65: Bayer AG: Key Employees Continued
Table 66: Lupin Ltd: key facts
Table 67: Lupin Ltd: Annual Financial Ratios
Table 68: Lupin Ltd: Key Employees
Table 69: Aspen Pharmacare Holdings Ltd: key facts
Table 70: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 71: Aspen Pharmacare Holdings Ltd: Key Employees
Table 72: EMS SA: key facts
Table 73: EMS SA: Key Employees
Table 74: Eurofarma Laboratorios SA: key facts
Table 75: Eurofarma Laboratorios SA: Key Employees
Table 76: Ache Laboratorios Farmaceuticos SA: key facts
Table 77: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 78: Apotex Inc: key facts
Table 79: Apotex Inc: Key Employees
Table 80: Teva Canada Ltd: key facts
Table 81: Teva Canada Ltd: Key Employees
Table 82: Sandoz Canada Inc: key facts
Table 83: Sandoz Canada Inc: Key Employees
Table 84: CSPC Pharmaceutical Group Ltd: key facts
Table 85: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 86: CSPC Pharmaceutical Group Ltd: Key Employees
Table 87: Sino Biopharmaceutical Ltd: key facts
Table 88: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 89: Sino Biopharmaceutical Ltd: Key Employees
Table 90: Hansoh Pharmaceutical Group Co Ltd: key facts
Table 91: Hansoh Pharmaceutical Group Co Ltd: Annual Financial Ratios
Table 92: Dr. Reddy's Laboratories Ltd: key facts
Table 93: Dr. Reddy's Laboratories Ltd: Annual Financial Ratios
Table 94: Dr. Reddy's Laboratories Ltd: Key Employees

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us